


CLAIMS

1. Compounds of formula:



5 in which:

- R<sub>1</sub> represents hydrogen or a (C<sub>1</sub>-C<sub>4</sub>)alkyl;
- R<sub>2</sub> represents:
  - . a (C<sub>3</sub>-C<sub>7</sub>)alkyl group,
  - . an indan-1-yl or 1,2,3,4-tetrahydronaphthalen-1-yl group,
  - 10 said groups being unsubstituted or substituted by a halogen atom and/or a methyl group;
  - . a saturated, single-nitrogen heterocyclic radical of 5 to 7
  - 15 atoms, the nitrogen atom being substituted by a (C<sub>1</sub>-C<sub>4</sub>)alkyl, benzyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxycarbonyl or (C<sub>1</sub>-C<sub>4</sub>)alkanoyl group;
  - . a group NR<sub>9</sub>R<sub>10</sub>;
  - 20 . a group (CH<sub>2</sub>)<sub>n</sub>R<sub>11</sub>, CH(CH<sub>3</sub>)R<sub>11</sub>, (CH<sub>2</sub>)<sub>m</sub>N(CH<sub>3</sub>)R<sub>11</sub>;
  - . a C<sub>3</sub>-C<sub>12</sub> nonaromatic carbocyclic

radical, unsubstituted or  
substituted one or more times by a  
methyl group;

- or R<sub>1</sub> and R<sub>2</sub> together with the nitrogen atom to  
5 which they are attached form either a piperazin-1-  
yl radical substituted in position 4 by a phenyl  
or benzyl group, or a piperidin-1-yl radical  
disubstituted in position 4 by a phenyl or benzyl  
group and by a (C<sub>1</sub>-C<sub>4</sub>)alkyl or (C<sub>1</sub>-C<sub>3</sub>)alkanoyl  
10 group; the phenyl or benzyl group substituents on  
the piperazin-1-yl radical or the piperidin-1-yl  
radical being unsubstituted or substituted by a  
halogen atom and/or a methyl group;
- R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> represent each  
15 independently of one another a hydrogen or halogen  
atom or a (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or  
trifluoromethyl group;
- R<sub>9</sub> and R<sub>10</sub> together with the nitrogen atom to which  
20 they are attached form a saturated or unsaturated  
heterocyclic radical of 5 to 10 atoms containing  
or not containing a second heteroatom selected  
from O and N, said radical being unsubstituted or  
substituted one or more times by a (C<sub>1</sub>-C<sub>4</sub>)alkyl,  
hydroxyl or (C<sub>1</sub>-C<sub>4</sub>)alkoxy group;
- 25 - R<sub>11</sub> represents: . a phenyl which is unsubstituted  
or substituted by one or more  
substituents selected from a

halogen atom and a methyl group;  
a heteroaryl radical of 6 to 10  
atoms containing one or more  
nitrogen atoms;

5 - n represents 1, 2 or 3;

- m represents 0, 2 or 3;

and their salts, their solvates and their hydrates.

2. A compound according to claim 1 of  
formula (I) in which:

10 - R<sub>1</sub> represents a hydrogen atom or a (C<sub>1</sub>-C<sub>4</sub>)alkyl  
group;

- R<sub>2</sub> represents a group NR<sub>9</sub>R<sub>10</sub> or a nonaromatic C<sub>3</sub>-C<sub>12</sub>  
carbocyclic radical which is unsubstituted or  
substituted one or more times by a methyl group;

15 - R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> represent each  
independently of one another a hydrogen or halogen  
atom or a (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or  
trifluoromethyl group;

- R<sub>9</sub> and R<sub>10</sub> together with the nitrogen atom to which  
20 they are attached form a saturated or unsaturated  
heterocyclic radical of 5 to 10 atoms, containing  
or not containing a second heteroatom selected  
from O and N, said radical being unsubstituted or  
substituted one or more times by a (C<sub>1</sub>-C<sub>4</sub>)alkyl  
25 group;


and their salts, their solvates and their hydrates.

3. Compounds according to claim 1 or claim

2 of formula (I) in which:


- $R_1$  represents a hydrogen atom; and/or
- $R_2$  represents a group selected from piperidin-1-yl, pyrrolidin-1-yl, cyclohexyl, spiro[5.5]undecanyl  
5 and 1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl;  
and/or
- at least one of the substituents  $R_3$ ,  $R_4$  and  $R_5$  represents a halogen atom or a trifluoromethyl group; and/or
- 10 - at least one of the substituents  $R_6$ ,  $R_7$  and  $R_8$  represents a halogen atom.

4. A process for preparing a compound of formula (I) according to any one of claims 1 to 3, characterized in that a functional derivative of  
15 terphenylic acid of formula:



in which  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$  and  $R_8$  are as defined for a compound of formula (I) in claim 1 is treated with an amine of formula  $\text{HNR}_1\text{R}_2$  (III) in which  $R_1$  and  $R_2$  are as  
20 defined for a compound of formula (I) in claim 1.

5. Compounds of formula:



in which  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$  and  $R_8$  are as defined for a compound of formula (I) in claim 1 and R represents a hydrogen atom or a  $(C_1-C_4)$ alkyl group, on condition that

5  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$  and  $R_8$  are not simultaneously hydrogen, and on condition that, when  $R_4$ ,  $R_5$ ,  $R_7$  and  $R_8$  represent hydrogen,  $R_3$  and  $R_6$  do not simultaneously represent a fluorine atom in meta position, or a methoxy group in meta or para position, and on

10 condition that when  $R_5$  and  $R_8$  represent hydrogen  $R_3$ ,  $R_4$  and  $R_5$ ,  $R_6$  do not simultaneously represent 3,4-dimethoxy groups.

6. A compound according to claim 5 of formula (IIa) in which:

- 15 -  $R_3$  is in position 4 and represents a halogen atom or a trifluoromethyl group;
- $R_6$  is in position 2 and represents a hydrogen or halogen atom;
- $R_7$  is in position 4 and represents a halogen atom;
- 20 -  $R_4$ ,  $R_5$  and  $R_8$  are hydrogen.

7. A medicinal product characterized in that it comprises a compound of formula (I) according

to any one of claims 1 to 3, or one of its pharmaceutically acceptable salts, hydrates or solvates.

8. A pharmaceutical composition
- 5 characterized in that it comprises a compound of formula (I) according to any one of claims 1 to 3, or one of its pharmaceutically acceptable salts, hydrates or solvates, and at least one pharmaceutically acceptable excipient.
- 10 9. The use of a compound of formula (I) according to any one of claims 1 to 3 for preparing a medicinal product intended for treating any disease involving the CB<sub>1</sub> cannabinoid receptor.
- 15 10. The use of a compound of formula (I) according to any one of claims 1 to 3 for preparing a medicinal product intended for treating psychotic disorders, memory and cognitive disorders, appetite disorders and obesity, or for tobacco withdrawal or alcohol withdrawal.